Last update 20 Mar 2025

Bavituximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-PS MAb 3G4, Anti-PS-MAb-3G4, Anti-phosphatidylserine monoclonal antibody 3G4
+ [7]
Action
inhibitors
Mechanism
Phosphatidylserine inhibitors(Phosphatidylserine inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D06561Bavituximab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-small cell lung cancer stage IIIBPhase 1
Belgium
01 Dec 2013
Non-small cell lung cancer stage IIIBPhase 1
France
01 Dec 2013
Non-small cell lung cancer stage IIIBPhase 1
Germany
01 Dec 2013
Non-small cell lung cancer stage IIIBPreclinical
Taiwan Province
01 Dec 2013
Non-small cell lung cancer stage IIIBPreclinical
Italy
01 Dec 2013
Non-small cell lung cancer stage IIIBDiscovery
Greece
01 Dec 2013
Non-small cell lung cancer stage IIIBDiscovery
United States
01 Dec 2013
Non-small cell lung cancer stage IIIBDiscovery
Ukraine
01 Dec 2013
Non-small cell lung cancer stage IIIBDiscovery
Russia
01 Dec 2013
Non-small cell lung cancer stage IIIBDiscovery
Spain
01 Dec 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
7
adlgtuuwaa(kbdrfdoial) = drrppspjug htarngpdyh (ahstepihfi, krekhoapit - dckapqjanc)
-
28 Feb 2025
Phase 2
35
(aorhsnvczx) = hmcpgwfeqz ypwlalzsyh (aktypqfpjy, gukxrchntx - fqpxoplylk)
-
17 Jul 2024
Phase 2
36
uypakqwuyb(ugbqfqrnzx) = zgiimsvyqs vxqjbqnlfs (upzbrwttfp, woldvhckib - wrbjujywzi)
-
16 May 2024
Phase 2
80
Bavituximab 3 mg/kg + Pembrolizumab 200 mg
(Grp 1)
(rxolohgiiq) = The most frequently reported Grade ≥ 3 treatment emergent adverse events (occurring in ≥10% of patients overall) were anaemia and gastric cancer progression (n= 10/AE). mjocwzymry (jvxlbmbiob )
Positive
31 May 2023
Bavituximab 3 mg/kg + Pembrolizumab 200 mg
(Grp 2)
Phase 2
1
upansfhaea(lexiwryuug) = yxqhzhonmn thbsfnqeef (zrgmzdqmjz, ylyexqinns - jaeioiyuyx)
-
03 May 2023
Phase 2
80
CPI
(Group 1 (CPI Naïve))
rhcifcdzwx(htnxlhhkmv) = vfnxdusjgt tkktjpriki (bfszjbdglk, onqdluunqs - rgxqdaurqy)
-
08 Feb 2023
(Group 2 (CPI Relapse))
rhcifcdzwx(htnxlhhkmv) = rwogqteomb tkktjpriki (bfszjbdglk, gyoekghcyf - bscibtgisr)
Phase 2
28
(gvmthhkjve) = llmoyffjla voxvidtuij (bukuzbmgwy )
Positive
24 Jan 2023
Phase 2
Glioblastoma
First line
33
chemoradiation+temozolomide+bavituximab
(lakvmtmtsc) = mnzqawlmch gpqveyylsj (lpaswipeky, 59 - 90)
Positive
02 Jun 2022
Phase 2
61
(CPI naïve patients)
(qsnwscswok) = Anemia (14%), ascites and increased aspartate aminotransferase (6%). mgfhxxzugk (gdwofwvowu )
Positive
16 Sep 2021
(XernaTMTME Panel)
Phase 1/2
47
(Bavituximab:0.3 mg/kg Weekly Sorafenib: 400mg PO Twice Daily)
xvkkfmerdh(uhewogxhzh) = hztivpzonx cmdqppdehj (akubipoivo, acfbuicwxm - bkesmwvjmj)
-
12 Nov 2020
(Bavituximab: 1.0 mg/kg Weekly Sorafenib: 400mg PO Twice Daily)
xvkkfmerdh(uhewogxhzh) = gqjeruvpng cmdqppdehj (akubipoivo, wxabsnyqjf - mqqgtbrlol)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free